Miotic Pharma

Miotic Pharma is a clinical-stage biopharmaceutical company focused on developing advanced ophthalmic treatments, particularly for presbyopia. Founded by the inventors of the first FDA-approved pharmacological treatment for presbyopia, the company aims to improve upon existing therapies through optimized formulations. Its lead program, MIO-102, is a proprietary pilocarpine-based solution designed to enhance near vision while minimizing common side effects such as brow ache and dimness. The company's strategy centers on leveraging deep expertise in ocular pharmacology to provide more effective and comfortable options for the aging eye. Miotic Pharma is currently advancing its pipeline through clinical trials to validate the safety and efficacy of its next-generation miotic agents.